ARTICLE | Company News
Confo Therapeutics N.V. (Brussels, Belgium) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to its small molecule agonists against an undisclosed GPCR.
Confo will receive a total of €6 million ($7.1 million) over 30 months, including an upfront payment, preclinical milestones and R&D funding. The biotech is also eligible for a further €81.5 million ($96.1 million) in milestones, plus tiered royalties...